Generated August 15, 2026.
Overview
VHT and XLV are both equity ETFs that track healthcare sectors of the US market, but they differ in scope and index construction. VHT tracks the MSCI US Investable Market Health Care 25/50 Index, which includes mid-cap and small-cap healthcare stocks alongside large-cap names. XLV tracks the Health Care Select Sector Index, which focuses on the healthcare component of the S&P 500, making it a large-cap concentrated play. The key distinction: VHT is broader; XLV is narrower and deeper into mega-cap exposure.
How they differ
XLV holds $41.9B in assets versus VHT's $18.3B, giving it roughly 2.3x the liquidity and tighter bid-ask spreads. The largest structural difference is index composition: XLV's Select Sector Index pulls only from the S&P 500, so it excludes mid and small-cap healthcare names that VHT captures through the MSCI index. That difference shows in beta—VHT's 0.57 versus XLV's 0.51—suggesting VHT has modestly higher market sensitivity, likely reflecting its exposure to smaller-cap volatility. On yield, XLV edges higher at 1.57% distribution rate versus VHT's 1.25%, though both pay quarterly. Expense ratios are nearly identical at 0.10% for VHT and 0.09% for XLV.
Who each is best for
VHT: Fits investors seeking diversified healthcare exposure across market capitalizations who tolerate moderate market sensitivity and value access to mid- and small-cap healthcare innovators alongside established leaders.
XLV: Fits investors who want large-cap healthcare stability and are comfortable with S&P 500–only composition, often preferring the simplicity of Select Sector indexing and higher absolute yield.
Key risks to know
- Index concentration: XLV's S&P 500–only constraint means it excludes potentially faster-growing mid-cap and small-cap healthcare firms captured by VHT's MSCI index. If smaller healthcare names outperform, XLV's narrower mandate could drag relative returns.
- Sector-level cyclicality: Both funds carry healthcare sector risk: regulatory changes, drug pricing pressure, clinical trial failures, and reimbursement shifts affect all holdings. A sector downturn will compress both portfolios.
- Overlap and correlation: Large-cap healthcare names will appear in both funds (Pfizer, Merck, UnitedHealth Group, Eli Lilly, and similar), so their price movements may correlate more than their different indexes suggest. Holding both offers limited diversification benefit.
- VHT's smaller AUM: With $18.3B versus XLV's $41.9B, VHT faces wider bid-ask spreads and lower trading liquidity, which can increase transaction costs for large positions.
Bottom line
If you want broad healthcare exposure spanning large, mid, and small caps, VHT's MSCI index provides it at minimal cost and a lower beta. If you prefer large-cap simplicity with higher current yield and prefer Select Sector construction, XLV's deeper liquidity and higher AUM make it the more accessible choice. Past performance does not predict future results; sector composition and index rules will drive future performance divergence.
AI-generated analysis for educational purposes only. Verify important details independently; past performance does not guarantee future results.